Corresponding Author: Rebecca S. Kearney, PhD, Warwick Clinical Trials Unit, University of Warwick, Coventry CV4 7AL, United Kingdom (r.s.kearney@warwick.ac.uk).
Accepted for Publication: April 19, 2021.
Author Contributions: Dr Kearney had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Kearney, Warwick, Parsons, Brown, Harrison, Young, Costa.
Acquisition, analysis, or interpretation of data: Kearney, Ji, Warwick, Parsons, Harrison, Costa.
Drafting of the manuscript: Kearney, Warwick, Parsons, Harrison, Young.
Critical revision of the manuscript for important intellectual content: Kearney, Ji, Warwick, Parsons, Brown, Costa.
Statistical analysis: Ji, Warwick, Parsons.
Obtained funding: Kearney, Parsons, Young, Costa.
Administrative, technical, or material support: Kearney, Parsons, Brown, Harrison, Costa.
Supervision: Kearney, Warwick.
Conflict of Interest Disclosures: Dr Kearney reported grants from Versus Arthritis during the conduct of the study and research grant funding from her institution (University of Warwick, which receives research funding from the UK National Institute for Health Research [NIHR], the National Health and Medical Research Council [NHMRC], Versus Arthritis, and orthopedic industry) outside the submitted work; and being coinvestigator on an NIHR-funded study receiving additional support from Stryker. Dr Ji reported grants from Versus Arthritis during the conduct of the study. Dr Warwick reported receiving grants from NIHR. Dr Parsons reported grants from Versus Arthritis during the conduct of the study. Dr Harrison reported funding by NIHR, Surgical Reconstruction and Microbiology Research Centre (SRMRC), and support from the Centre for Conflict Wound Research (which is funded by the Scar Free Foundation through a grant from the chancellor using London Interbank Offered Rate [LIBOR] funds. Dr Costa reported grants from his institution (University of Oxford, which receives research grant funding from the UK NIHR, the European Union, NHMRC, Versus Arthritis, Heraeus Medical GmbH, and SOTA Orthopaedics) outside the submitted work. No other disclosures were reported.
Funding/Support: This trial was funded by Versus Arthritis commencing on September 1, 2015 (Versus Arthritis 20831).
Role of the Funder/Sponsor: Versus Arthritis and the University of Warwick had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: The views expressed are those of the author(s) and not necessarily those of the Versus Arthritis.
Group Information: The ATM Trial Collaborators appear in Supplement 4.
Data Sharing Statement: See Supplement 5.
Additional Contributions: We would like to thank all the patients and the research support at each recruitment centre that made the trial a success. The research team would also like to acknowledge Karen Keates, the patient and public involvement representative; Philip Moss (University of Warwick), data collection; Martin Underwood, MD (University of Warwick), interim maternity cover chief investigator; and the trial steering committee and data monitoring and ethics committee for their contribution throughout the feasibility and main trial. These roles were supported through the Versus Arthritis research grant.